Press releases
2023
Curasight to present at HC Andersen Capital and Økonomisk Ugebrev
May 26, 2023
| Regulatory
Copenhagen, Denmark, 26 May 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q1 2023 at HC Andersen Capital and at Økonomisk Ugebrev, 31 May 2023.
Interim report Q1 2023
May 25, 2023
| Regulatory
Copenhagen, Denmark, 25 May 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer
May 1, 2023
| Regulatory
· Curasight to develop its proprietary uTRACE[®] PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for manufacturing and commercialization
· Curasight eligible for up to USD 70 mn in development and commercial milestones as well as double-digit royalties on sales on eventual commercialization
· The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer
Resolutions of the Annual General Meeting of Curasight A/S
March 30, 2023
| Regulatory
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held its Annual General Meeting on 30 March 2023 at 10:00 (CET) at the Company’s premises, Ole Maaløes Vej 3, room M3.10, DK-2200 Copenhagen N, Denmark.
Notice of Annual General Meeting 2023
March 15, 2023
| Regulatory
Copenhagen, Denmark, 15 March 2023 – Notice is hereby given of the annual general meeting of Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS).
The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S, to be held on
Thursday 30 March 2023 at 10:00 AM (CEST) at COBIS, Ole Maaløes Vej 3, DK-2200 Copenhagen
The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S, to be held on
Thursday 30 March 2023 at 10:00 AM (CEST) at COBIS, Ole Maaløes Vej 3, DK-2200 Copenhagen
Annual Report for the fiscal year 2022
February 23, 2023
| Regulatory
Copenhagen, Denmark, 23 February 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year of 2022. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Year-end report October - December 2022
February 23, 2023
| Regulatory
Copenhagen, Denmark, 23 February 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Year-end report October – December 2022. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight to present at HC Andersen Capital
February 22, 2023
| Regulatory
Copenhagen, Denmark, 22 February 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Annual Report 2022 and Year-End Report Q4 2022 at HC Andersen Capital, 27 February 2023.
Curasight to present at Redeye Fight Cancer Seminar
January 16, 2023
| Regulatory
Copenhagen, Denmark, 16 January 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company at Redeye Fight Cancer Seminar Outlook - January 19, 2023.
2022
Interim Report January – September 2022
November 24, 2022
| Regulatory
Copenhagen, Denmark, 24 November 2022 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – September 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.